首页 > 市场调查报告书 > 製药

疫苗

市场调查报告书

商品编码

1562307

中东和非洲人类疫苗佐剂市场预测至 2030 年 - 区域分析 - 按类型、应用（流感、肝炎、人类乳突病毒等）和最终用户

Middle East & Africa Human Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Type, Application (Influenza, Hepatitis, Human papilloma virus, and Others), and End User

出版日期: 2024年07月04日 | 出版商:

The Insight Partners | 英文 109 Pages | 订单完成后即时交付

价格

简介目录图表

2022年中东和非洲人用疫苗佐剂市场价值为4,918万美元，预计2030年将达到1,1937万美元；预计2022年至2030年复合年增长率为11.7%。

慢性病盛行率上升提振中东和非洲人类疫苗佐剂市场

慢性病盛行率的上升推动了对疫苗佐剂的需求。疫苗中添加佐剂以增强功效和身体的免疫反应。它们透过刺激更强、更持久的免疫反应来帮助提高疫苗的有效性。随着预防和管理慢性病的疫苗需求持续成长，佐剂的需求也随之增加。心血管疾病、癌症、糖尿病和呼吸系统疾病等慢性疾病在全球呈现上升趋势。据世界卫生组织称，与非传染性疾病相关的死亡最多的是心血管疾病，每年约造成 1700 万人死亡，其次是癌症、慢性呼吸道疾病和糖尿病（包括与肾臟相关的死亡）。此外，根据世界心臟联盟的数据，高胆固醇每年导致 440 万人死亡，约 24% 的心血管相关死亡可归因于高低密度脂蛋白 (LDL) 胆固醇。因此，慢性病负担的增加导致对能够预防或控制这些疾病的疫苗的需求不断增长。肝炎的盛行率也在增加。肝炎疫苗中的佐剂旨在引发强大而持久的免疫力，特别是对标准疫苗配方反应不佳的人群，例如患有潜在疾病或与年龄相关的免疫衰老的人群。据世界卫生组织称，全世界有超过 3.5 亿人患有乙型或丙型肝炎。根据世界卫生组织的一项研究，到 2030 年，低收入和中等收入国家估计可透过疫苗接种预防 450 万人因肝炎而过早死亡。因此，慢性病盛行率的增加推动了中东和非洲人类疫苗佐剂市场的成长。

中东和非洲人用疫苗佐剂市场概况

作为国家转型计划的一部分，沙乌地阿拉伯计划将 40% 的製药业在地化，并减少其进口依赖。在沙乌地阿拉伯，经济和社会变化导致久坐生活方式的转变，导致肥胖盛行率不断上升，代谢症候群预计也会增加。此外，患者缺乏疾病意识和关于疾病传播的知识，增加了该国传染病的盛行率。例如，根据2023 年PubMed 发表的一项研究《沙乌地阿拉伯和阿联酋的乙型肝炎病毒感染：公共卫生挑战及其补救措施》，即使在实施了乙型肝炎病毒治疗和管理后，沙乌地阿拉伯在乙型肝炎病毒治疗和管理方面仍面临严峻挑战大规模疫苗接种计画。同样，根据 ICO/IARC 资讯中心 2023 年 HPV 和癌症报告，沙乌地阿拉伯有 1,070 万 15 岁及以上女性人口，有 HPV 相关子宫颈癌的风险。因此，阿联酋传染病日益普及加剧了对人类疫苗佐剂的需求。近年来，沙乌地阿拉伯王国在医疗保健和製药领域进行了大量投资，旨在增强国内生产、研发能力。这项策略重点为潜在成长奠定了基础，影响了中东和非洲人类疫苗佐剂市场。在沙乌地阿拉伯，法赫德国王医疗城、费萨尔国王专科医院和研究中心以及卫生部等机构积极参与推进医疗保健研究，包括与疫苗和佐剂相关的研究。对研究设施和医疗基础设施的此类投资标誌着我们致力于为全球疫苗领域做出贡献。它还预计将为佐剂研究和开发进步铺平道路。

中东和非洲人类疫苗佐剂市场收入及 2030 年预测（百万美元）

中东和非洲人用疫苗佐剂市场区隔

中东和非洲人疫苗佐剂市场按类型、应用、最终用户和国家分类。

根据类型，中东和非洲人用疫苗佐剂市场分为颗粒佐剂、乳液佐剂、组合佐剂等。 2022 年，颗粒助剂领域占最大的市场份额。

从应用来看，中东和非洲人疫苗佐剂市场分为流感、肝炎、人类乳突病毒（HPV）等。 2022 年，流感细分市场占据最大市场。

以最终用户划分，中东和非洲人疫苗佐剂市场分为製药和生技公司、CMO 和 CRO 等。 2022 年，製药和生物技术公司领域占据最大的市场份额。

依国家划分，中东和非洲人疫苗佐剂市场分为沙乌地阿拉伯、南非、阿联酋以及中东和非洲其他地区。 2022年，沙乌地阿拉伯在中东和非洲人类疫苗佐剂市场份额中占据主导地位。

Novartis AG、CSL Ltd、Seppic SA、Croda International Plc、Novavax Inc 和 Phibro Animal Health Corp 是中东和非洲人类疫苗佐剂市场的一些领先公司。

The rising prevalence of chronic diseases is fueling the demand for vaccine adjuvants. Adjuvants are added to vaccines to enhance the efficacy and body's immune response. They help improve the effectiveness of vaccines by stimulating a stronger and longer-lasting immune response. As the demand for vaccines to prevent and manage chronic diseases continues to grow, the demand for adjuvants also increases. Chronic diseases such as cardiovascular diseases, cancer, diabetes, and respiratory diseases are rising globally. According to the World Health Organization, the most noncommunicable disease-related deaths are cardiovascular diseases, accounting for ~17 million people each year, followed by cancers, chronic respiratory diseases, and diabetes (including deaths associated with the kidney). Furthermore, according to the World Heart Federation, high cholesterol causes 4.4 million deaths yearly, and ?24% of cardiovascular-related deaths are attributable to high low-density lipoprotein (LDL) cholesterol. Thus, the increasing burden of chronic diseases has led to a growing demand for vaccines that can prevent or manage these conditions. The prevalence of hepatitis is also increasing. Adjuvants in hepatitis vaccines aim to elicit robust and durable immunity, particularly in populations with suboptimal responses to standard vaccine formulations, such as those with underlying medical conditions or age-related immune senescence. According to the WHO, more than 350 million people worldwide live with hepatitis B or C. Among all types of hepatitis, several are preventable through vaccination. As per a study by WHO, an estimated 4.5 million premature deaths due to hepatitis could be prevented in low- and middle-income countries by 2030 through vaccination. Thus, the increasing prevalence of chronic diseases drives the growth of the Middle East & Africa human vaccine adjuvants market.

Middle East & Africa Human Vaccine Adjuvants Market Overview

Saudi Arabia has planned to localize 40% of the pharmaceutical sector and reduce its import dependence as part of its National Transformation Program. In Saudi Arabia, economic and social changes have led to a shift in sedentary lifestyles, leading to an increasing prevalence of obesity and a projected rise in metabolic syndrome. Furthermore, a lack of disease awareness and knowledge about disease transmission among patients has increased the prevalence of infectious diseases in the country. For instance, according to a study, "Hepatitis B virus infection in Saudi Arabia and the UAE: Public health challenges and their remedial measures," published in PubMed in 2023, Saudi Arabia faces critical challenges in Hepatitis B virus treatment and management even after implementing a mass vaccination program. Similarly, according to a report by ICO/IARC Information Centre on HPV and Cancer in 2023, Saudi Arabia has a population of 10.7 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. Thus, the increasing prevalence of infectious diseases in the UAE fuels the demand for human vaccine adjuvants. In recent years, the Kingdom of Saudi Arabia has invested substantially in the healthcare and pharmaceutical sectors, aiming to enhance domestic production, research, and development capabilities. This strategic focus has set the stage for potential growth, influencing the Middle East & Africa human vaccine adjuvants market. In Saudi Arabia, the King Fahd Medical City, King Faisal Specialist Hospital & Research Centre, and the Ministry of Health are among the institutions actively involved in advancing healthcare research, including those related to vaccines and adjuvants. Such investment in research facilities and medical infrastructure signals a commitment to contributing to the global vaccine landscape. It is also projected to pave the way for adjuvant research and development advancements.

Middle East & Africa Human Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

Middle East & Africa Human Vaccine Adjuvants Market Segmentation

The Middle East & Africa human vaccine adjuvants market is categorized into type, application, end user, and country.

Based on type, the Middle East & Africa human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held the largest market share in 2022.

In terms of application, the Middle East & Africa human vaccine adjuvants market is categorized into influenza, hepatitis, human papilloma virus (HPV), and others. The influenza segment held the largest market share in 2022.

By end user, the Middle East & Africa human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest market share in 2022.

By country, the Middle East & Africa human vaccine adjuvants market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa human vaccine adjuvants market share in 2022.

Novartis AG, CSL Ltd, Seppic SA, Croda International Plc, Novavax Inc, and Phibro Animal Health Corp are some of the leading companies operating in the Middle East & Africa human vaccine adjuvants market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Middle East & Africa Human Vaccine Adjuvants Market - Key Market Dynamics

4.1 Middle East & Africa Human Vaccine Adjuvants Market - Key Market Dynamics
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Chronic Diseases
- 4.2.2 Growing Focus on Immunization Programs
4.3 Market Restraints
- 4.3.1 Manufacturing Complexities and Regulatory Challenges
4.4 Market Opportunities
- 4.4.1 Growing Pharmaceutical Industry
4.5 Future Trends
- 4.5.1 Rising Trend of Personalized Vaccines
4.6 Impact of Drivers and Restraints:

5. Human Vaccine Adjuvants Market - Middle East & Africa Market Analysis

5.1 Middle East & Africa Human Vaccine Adjuvants Market Revenue (US$ Million), 2020 - 2030
5.2 Middle East & Africa Human Vaccine Adjuvants Market Forecast Analysis

6. Middle East & Africa Human Vaccine Adjuvants Market Analysis - by Type

6.1 Particulate Adjuvant
- 6.1.1 Overview
- 6.1.2 Particulate Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.2 Emulsion Adjuvant
- 6.2.1 Overview
- 6.2.2 Emulsion Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Combination Adjuvant
- 6.3.1 Overview
- 6.3.2 Combination Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Others
- 6.4.1 Overview
- 6.4.2 Others: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. Middle East & Africa Human Vaccine Adjuvants Market Analysis - by Application

7.1 Influenza
- 7.1.1 Overview
- 7.1.2 Influenza: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Hepatitis
- 7.2.1 Overview
- 7.2.2 Hepatitis: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Human papilloma virus (HPV)
- 7.3.1 Overview
- 7.3.2 Human Papilloma Virus (HPV): Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Others
- 7.4.1 Overview
- 7.4.2 Others: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Middle East & Africa Human Vaccine Adjuvants Market Analysis - by End User

8.1 Pharmaceutical and Biotechnology Companies
- 8.1.1 Overview
- 8.1.2 Pharmaceutical and Biotechnology Companies: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.2 CMOs and CROs
- 8.2.1 Overview
- 8.2.2 CMOs and CROs: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9. Middle East & Africa Human Vaccine Adjuvants Market - Country Analysis

9.1 Middle East & Africa
- 9.1.1 Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  - 9.1.1.1 Saudi Arabia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.1.1 Saudi Arabia Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.1.2 Saudi Arabia Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.1.3 Saudi Arabia Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.2 South Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.2.1 South Africa Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.2.2 South Africa Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.2.3 South Africa Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.3 United Arab Emirates Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.3.1 United Arab Emirates Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.3.2 United Arab Emirates Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.3.3 United Arab Emirates Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.4 Rest of Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.4.1 Rest of Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.4.2 Rest of Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.4.3 Rest of Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by End User

10. Industry Landscape

10.1 Overview

11. Company Profiles

11.1 Novartis AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 CSL Ltd
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Seppic SA
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Croda International Plc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Novavax Inc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Phibro Animal Health Corp
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms

简介目录图表

List Of Tables

Table 1. Middle East & Africa Human Vaccine Adjuvants Market Segmentation
Table 2. Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Table 3. Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Type
Table 4. Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 5. Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by End User
Table 6. Saudi Arabia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 7. Saudi Arabia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 8. Saudi Arabia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 9. South Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 10. South Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 11. South Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 12. United Arab Emirates Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 13. United Arab Emirates Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 14. United Arab Emirates Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 15. Rest of Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 16. Rest of Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 17. Rest of Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 18. Recent Growth Strategies in the Human Vaccine Adjuvants Market
Table 19. Glossary of Terms, Human Vaccine Adjuvants Market

List Of Figures

Figure 1. Middle East & Africa Human Vaccine Adjuvants Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Middle East & Africa Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 - 2030
Figure 4. Middle East & Africa Human Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
Figure 5. Particulate Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Emulsion Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Combination Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Middle East & Africa Human Vaccine Adjuvants Market Share (%) - by Application (2022 and 2030)
Figure 10. Influenza: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Human papilloma virus (HPV): Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Middle East & Africa Human Vaccine Adjuvants Market Share (%) - by End User (2022 and 2030)
Figure 15. Pharmaceutical and Biotechnology Companies: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. CMOs and CROs: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Key Countries - Revenue (2022) (US$ Million)
Figure 19. Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 20. Saudi Arabia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 21. South Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 22. United Arab Emirates Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 23. Rest of Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)